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of immunosuppression (WHO criteria), use of antiretroviral 
therapy, CD4 counts, location of lesions, treatment used 
(surgery, chemotherapy, radiotherapy, combination), 
treatment duration, and estimates on survival. SPSS version 
20 was used in the statistical analysis. 
Results: A total of 63 cases fit the study criteria out of 113 
seen. Ratio of Epidemic vs. Endemic KS was 1: 1.8. Male to 
female ratio was 2.5: 1.The median age at presentation was 
48yrs (range 18-80yrs). The most frequent site was skin (90%) 
with 84% on the lower extremity and 6% disseminated. About 
60% of the HIV positive patients were on HAART. Median CD4 
count was 250cells/mm3 (range 1-549). Twenty four percent 
of the patients had both chemotherapy and radiotherapy, 
16% had chemotherapy only, 22% had radiotherapy only and 
38% refused treatment. The commonest chemotherapeutic 
agent used was Vincristine and others were Paclitaxel, 
Doxorubicin and Bleomycin. In all, 72% of the patients who 
received radiotherapy had good control with a minimum BED 
of 17.6Gy, out of which 52% had BED of 20Gy or less, 43% had 
BED between 20Gy and 40Gy and 5% greater than 40Gy. The 
most frequently prescribed radiation dose was 8Gy as a single 
dose. Other dose prescriptions used were 20Gy in 5 fractions 
and 30Gy in 10 fractions. The median follow period was 85 
days (range 1- 2241days). The overall survivals at 5years and 
10years were 41% and 6% respectively. 
Conclusions: The pattern of Kaposi’s sarcoma in Ghana 
differs from that of other Sub-Saharan African countries due 
to a relatively low rate of HIV infections, with endemic 
Kaposi sarcoma being almost twice as common. Radiotherapy 
is associated with good and durable local control to 
symptomatic sites. A BED at least 17.6Gy is required for local 
control of the disease. Follow up was however a limitation to 
this study. 
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Purpose/Objective: Breast sarcoma is a rare malignancy 
accounting for less than 1 percent of all breast malignancies 
and <5% of all soft tissue sarcomas It is a histologically 
heterogeneous non-epithelial malignancy arising from the 
breast connective tissue. Breast sarcoma can develop de novo 
or following radiation therapy. We present a case series 
analysis of all breast cancer sarcomas presented to our 
institution in a 14 year period. 
Materials and Methods: Data was retrospectively collected 
on all patients presenting with a histological diagnosis of 
breast sarcoma between 1999 and 2012. All cases have had 
histological confirmation of sarcoma diagnosis. Information 
collected on: age at diagnosis, presentation, tumour size, 
pathological and radiographic findings, treatment, breast 
cancer mortality and past medical history including prior 
radiotherapy. 
Results: Twenty-two patients were identified aged between 
15 and 84 (mean 54 years). Ten cases were in the right breast 
and ten within the left breast, one case was bilateral. 
Sixteen cases presented as a primary breast sarcoma, five 
presented as metastasis to the breast and skin overlying the 
breast, one presented as a metastasis from the breast. 
Tumour size was available for seventeen specimens ranging 
between 6mm and 130mm (mean 44.47mm). 
Histopathological diagnosis included sarcoma (not further 
specified) n=2, rhabdomyosarcoma n=3, myofibroblastic 
sarcoma n=2, leimyosarcoma n=1, angiosarcoma n=5, 
desmoids tumour with fibromatosis n=1, osteosarcoma n=1, 
liposarcoma n=1, spindle cell sarcomatosis n=1, stromal 
sarcoma n=2. 3 specimens revealed sarcomatoid features of 
uncertain origin. Surgical management included mastectomy 
(n=7), wide local excision (n=9), lumpectomy (n=3), one 
patient declined operative management and three patients 
lacked full clinical details.Ten patients presented with 
sarcoma in a previous radiotherapy field of which five of 
these were histologically angiosarcoma. Local recurrence was 
observed in two patients, two patients had distant metastatic 
disease. five patients presented with metastatic disease to 
the breast or the overlying skin, sixteen tumours presented 
primarily in the breast and one presented as metastasis to 
the tonsil.Ten of the twenty two patients died with a 
diagnosis of breast cancer. Tumour size > 5cm was not 
significantly associated with 5 year overall survival(p=0.63) in 
17 specimens for which tumour size was available. Influence 
of tumour grade on overall survival was not assessed due to 
insufficient clinical details. 
Conclusions: Our results indicate that prognosis in patients 
with breast sarcoma is still poor. Larger cohort of patients 
and more clinical research is required to improve treatment 
outcomes in patients with breast sarcomas. 
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Purpose/Objective: To assess the feasibility and local control 
of adjuvant radiotherapy in patients with BM after surgery. 
To analyze prognostic factors. 
Materials and Methods: 49 patients with resected BM from 
the lung, breast, gastrointestinal, genitourinary, and 
unknown origin were recruited (43 patients with 1 lesion and 
6 patients with 2 lesions). Ten patients were RPA class I, 38 
patients class II, and 1 patient class III. The GPA score was 
0.5 in 1 patient, 1.5 in 15 patients, 2.0 in 8 patients, 2.5 in 5 
patients, 3.0 in 12 patients, 3.5 in 6 patients, and 4.0 in 2 
patients. 24 out of 49 patients had synchronous BM. 
Results: A total of 11 patients received a single treatment 
session, 27 patients received hypofractionated stereotactic 
radiation regimen, while 11 cases were treated with focal 3D 
radiation with/without cone beam. After a median follow-up 
of 15.2 months, the median disease-free progression time 
was 11.3 months (95% CI, 6.4-16.3). The actuarial local 
